Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Director Sells 12,583 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 12,583 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the sale, the director directly owned 38,743 shares of the company’s stock, valued at approximately $2,716,271.73. This trade represents a 24.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, June 11th, Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock. The stock was sold at an average price of $70.13, for a total transaction of $1,572,104.21.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $58.97, for a total value of $6,191,850.00.

Oruka Therapeutics Price Performance

Shares of ORKA stock traded up $1.42 during trading on Friday, reaching $69.89. The company’s stock had a trading volume of 781,454 shares, compared to its average volume of 1,072,342. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of -36.03 and a beta of -0.26. The stock’s 50-day moving average price is $63.01 and its 200 day moving average price is $43.76. Oruka Therapeutics, Inc. has a 1-year low of $10.77 and a 1-year high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ORKA has been the topic of several recent research reports. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 14th. UBS Group lifted their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at $37,000. PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics during the third quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at $67,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $43,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.